Summary The production of insulin-like growth factor I (IGF-I) and IGF-I binding proteins (BPs) by human lung tumour cell lines in vitro has been examined and the levels of these substances in the serum of lung cancer patients investigated. While small cell lung cancer (SCLC) cell lines secreted both IGF-I and BPs, non-small cell lung cancer (NSCLC) cell lines secreted BPs only. No evidence of increased serum IGF-I levels was obtained in a cohort of 52 lung cancer patients having SCLC and NSCLC histologies. In contrast, serum levels of low molecular weight BPs were markedly elevated in the majority of lung cancer patients.
The detection of elevated immunoreactive insulin-like growth factor-I (IGF-I) in human lung tumours (Minuto et al., 1986; Macaulay et al., 1988a) together with the observed secretion of immunoreactive IGF-I by selected small cell lung cancer (SCLC) cell lines in vitro (Jacques et al., 1988) raises the possibility that IGF-I may be a clinically valuable serological tumour marker in patients with lung tumours. However, in a recent study of 42 untreated patients with histologically confimed SCLC, evidence of elevated IGF-I levels was obtained in two patients only (Macaulay et al., 1988b ). The present study was initiated to investigate further the secretion of IGF-I by lung tumour cell lines in vitro and circulating IGF-I levels in SCLC and non-small cell lung cancer (NSCLC) patients. Since IGFs circulate in the blood complexed to two different classes of binding protein (BP) (Rinderknecht & Humbel, 1978; Smith, 1984) elimination of BPs by effective extraction procedures is generally essential for accurate quantification of IGF-I levels (Daughaday et al., 1980; Baxter, 1986) . BPs may lead to high values if the tracer complexes to them, or may result in low values if ligand-BP interaction is of high affinity, rendering bound ligand unavailable for reaction with antibody. During the course of this study it was noted that in contrast to unextracted sera from healthy controls, unextracted sera from lung cancer patients gave markedly higher IGF-I values, as determined by radioimmunoassay, than extracted sera, perhaps suggesting the presence of BPs in the lung cancer group. We here report the production of both immunoreactive IGF-I and BPs by lung tumour cells in vitro and the detection of elevated serum levels of BPs but not IGF-I in SCLC and NSCLC patients.
Materials and methods
Cell conditioned media Full details of the derivation and characterisation of classic SCLC cell lines COR-L51 and COR-L47, variant SCLC cell lines COR-L24 and COR-L103, large cell lung cancer cell line COR-L23 and B-lymphoblastoid lines COR-L26 and COR-L65 have been previously described (Baillie-Johnson et al., 1985) . Classic SCLC cell line NCI-H69 (Gazdar et al., 1986) (Wilkins & D'Ercole, 1985) to give a final concentration of 1 mM followed by incubation at room temperature for O min. To confirm the specificity of the cross linking, the reaction was carried out in the presence or absence of 500 ng of cold IGF-I. Samples were prepared for electrophoresis by the addition of 0.0005% bromophenol blue in 0.015 M Tris-HCI (pH 8.8). Electrophoresis was performed on 7-15% linear gradient gels overnight at room temperature with a constant current of 8 mA. Gels were fixed in 3.5% acetic acid/10.5% methanol and autoradiographed. Chromatography Gel filtration chromatography was performed using a 2.5 x 1,000cm (bed volume = 465 ml) Sephacryl S 200 HR (Pharmacia) column. Serum samples were eluted at 4°C in 0.1 M potassium phosphate buffer (pH 7.4) containing 0.15 M NaCl and collected in 3 ml fractions which were monitored for protein by determination of optical density at 280 nm. Aliquots of fractions showing apparent immunoreactivity in the Amersham RIA were affinity labelled with '251I-IGF-I in the presence or absence of 500 ng IGF-I as described above.
Results

Detection of immunoreactive IGF-I in cell conditioned media
The concentrations of IGF-I in extracted conditioned media as measured by the IDS IRMA are shown in Table I Reactive fractions were then affinity labelled with '251-IGF-I as described in Materials and methods, subjected to SDS gel electrophoresis and autoradiographed.
For control sera, IGF-I immunoreactivity was detected by both IDS-IRMA and Amersham RIA in fractions containing proteins slightly smaller than the y-globulin peak (apparent Mr of 150 kDa). A second smaller peak of reactivity eluted from the column just after the albumin peak (apparent Mr of 50 kDa) (Figure 2a ). (Figure 2b ). Although these complexes were detected in equivalent fractions from normal sera (Figure 2a) Non-smoking controls 15 0 not BPs. These findings indicate that the synthesis of IGF-I and BPs may occur independently in some tumour cell lines in vitro but that in SCLC cells IGF-I synthesis is consistently associated with that of BPs.
The observations that SCLC cell lines release IGF-I, express IGF-I receptors and respond mitogenically to IGF-I (Jacques et al., 1988) suggest that IGF-I may be an autocrine growth factor for SCLC tumours. Interestingly, several lines of evidence suggest that BPs are involved in the modulation of IGF-I mediated mitogenesis. BPs have been shown to inhibit the effects of IGF-I and IGF-II on fibroblast DNA synthesis (Knauer & Smith, 1980) . Binding of these proteins to cell surfaces increases the binding of IGF-I to its receptor (Clemmons et al., 1986) and IGF-I BPs have been shown markedly to potentiate the replication of human mouse and chicken embryo fibroblasts in response to IGF-I stimulation (Elgin et al., 1987) . Hence the production of IGF-I BPs by SCLC cells raises the possibility that these proteins similarly modulate the mitogenic responsiveness of SCLC to IGF-I stimulation. Studies are currently in progress to investigate this possibility.
The present study also shows that although significant amounts of IGF-I are produced by SCLC cells in vitro, serum IGF-I levels are not raised in lung cancer patients compared to normal controls. The apparently elevated levels of IGF-I in the unextracted sera of cancer patients were clearly due to BP effects as evidenced by the detection of IGF-I binding proteins in cancer patient serum fractions having reactivity in the Amersham RIA and by the results obtained for extracted sera. The observation that serum levels of IGF-I are not increased in SCLC patients, though consistent with those of earlier reports (Minuto et al., 1986; Macaulay et al., 1988b) , is perhaps surprising given the over-production of BPs in lung cancer patients and the ability of BPs to prolong the half life of IGFs in the circulation (Cohen & Nissley, 1976; Zapf et al., 1979) . One explanation is that the release of IGF-I from SCLC cells in vivo is, like IGF-I release from liver, hormonally regulated by mechanisms which do not exist in vitro. Alternatively, if IGF-I is indeed an autocrine growth factor for SCLC cells, secreted IGF-I may rapidly associate with IGF-I receptors and may be subsequently internalised and degraded. Significant changes in serum levels of the autocrine growth factor gastrin releasing peptide are similarly only rarely seen (Pert & Schumacher, 1982) .
In contrast to IGF-I, serum levels of low molecular weight BPs were markedly elevated in SCLC and NSCLC patients compared to normal healthy non-smokers and most healthy smokers. Although affinity labelling does not yield an autoradiographic signal proportional to the amount of protein present and is affected by binding site occupancy, the observed production of BPs by lung tumour cells in vitro supports the contention that there is a quantitative increase in circulating BPs in lung cancer patients. The frequency with which BP abnormalities were detected in lung cancer patients raises the possibility that IGF-I BPs may be clinically useful tumour markers for both SCLC and NSCLC tumours. Indeed our preliminary studies indicate that BP levels reflect tumour burden and may also be of value in disease monitoring.
The lung tumour derived 25-30 kDa BPs produced by lung tumour cell lines in vitro and also detected in the serum of lung cancer patients are also present in the serum of normal healthy individuals. Hence they are likely to belong to the family of small molecular weight BPs which are growth hormone independent (Hardouin et al., 1987; Hintz et al., 1981; Hall et al., 1988) . Proteins of this group have been termed placental protein 12 (ppl2) (Koishnen et al., 1986) , BP28 (Baxter et al., 1987) , IGFBP-25 (Lee et al., 1988) , IBP-1 (Brinkman et al., 1988) and pregnancy associated endometrial-y-globulin (Bell & Keyte, 1988) .
Amino acid sequence analyses indicate that many of the smaller molecular weight BPs characterised to date are, in fact, a single protein encoded by the IBP-1 gene (Lee et al., 1988; Brinkman et al., 1988; Baxter & Martin, 1989) . Recently, however, a novel human binding protein IGFBP-2 has been identified with a predicted molecular weight of 31 kDa (Binkert et al., 1989) which has a higher affinity for IGF-II than IGF-I and which is encoded by the IGFBP-2 gene. Studies are in progress to investigate the relationship between lung tumour IGF-BPs and the different low molecular weight IBP-1 and IGFBP-2 BPs.
Serum concentration of the smaller molecular weight BP is influenced by a variety of physiological factors (Baxter & Martin, 1989) . In normal subjects the levels of BP fall from birth to adulthood, increase during pregnancy, show diurnal rhythmicity, vary inversely with growth hormone status and increase with hypoglycaemia. Increased serum levels have been observed in trophoblastic disease, pre-eclampsia and ovarian cancer (Baxter & Martin, 1989) . In the present study blood samples were taken from patients and controls at approximately equivalent times, there were no cases of pregnancy in either group and no evidence of hypoglycaemia in cancer patients when pre-treatment blood samples were taken. Hence it is unlikely that the elevated levels of BPs detected in cancer patient sera compared to normal controls are due to factors which normally influence BP serum concentration. The observation that serum levels of the low molecular weight BPs are apparently increased in some healthy smokers is of interest and under further investigation.
